Syntara Limited has released a press release.
Fourth Quarter Activity Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Pharmaxis Quarterly Shareholder Update - March 2020
- PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
- Quarterly Shareholder Update - December 2019
- Pharmaxis Business Plan Update
- Quarterly Shareholder Update - September 2019
Later from Syntara
- US$7 million Bronchitol Launch Milestone Brought Forward
- FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
- Pharmaxis Awarded $1M Australian Government Grant
- Boehringer Ingelheim discontinues development of BI 1467335
- September Quarter 2020 Activity Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara